The shiny veil of AI - between hype and reality in pharmaceutical sales

The last few months have catapulted us in pharmaceutical sales into a fascinating, if sometimes confusing, new world: the world of artificial intelligence. Fuelled by the impressive advances of OpenAI, suddenly anything seemed possible. Marketing experts saw AI as the long-awaited game changer, the tool to maximise impact with minimal effort. Type in a few keywords and voilà - customised answers, creative texts, seemingly limitless possibilities. But in the midst of this initial euphoria, a crucial question arises: is this shiny veil of AI really as sustainable as it seems?

A look at the digital discussion forums, above all LinkedIn, paints a clear picture of the current AI debate. We observe two main groups: those who are impressed by the sheer imagination of the technology, often without in-depth technical understanding, and the enthusiastic tech nerds who happily welcome and test every new development. But where is the voice of those who are supposed to integrate this technology into their daily workflow in pharmaceutical sales? Where are the concrete use cases that go beyond mere experimentation and provide real, measurable benefits?

The initial enthusiasm is slowly giving way to a noticeable disillusionment. The high expectations were often not met and the promised miracles failed to materialise. Superficial hype, it seems, is not a solid foundation for sustainable and effective support of marketing and sales strategies.

In the upcoming articles in this series, we will delve deeper into this topic. We will shed light on the challenges that arise when implementing AI in the complex environment of pharmaceutical sales and, above all, discuss solutions and best practices that go beyond mere hype and can create real added value. Stay tuned!